Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
June 23, 2022 07:30 ET
|
Diffusion Pharmaceuticals Inc.
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise intervalPositive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to...
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”
December 20, 2021 07:02 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial
December 16, 2021 08:59 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523
December 01, 2021 07:02 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Doses First Participants in Altitude Trial
November 22, 2021 07:02 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
November 10, 2021 07:02 ET
|
Diffusion Pharmaceuticals Inc.
Announces Intent to Develop TSC to Treat Hypoxic TumorsAltitude Trial Expected to Commence in November 2021ILD-DLCO Trial Expected to Commence in Late December 2021 CHARLOTTESVILLE, Va., Nov. ...
Diffusion Pharmaceuticals Issues Letter to Shareholders
September 09, 2021 07:32 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference
September 08, 2021 07:32 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division
August 30, 2021 07:32 ET
|
Diffusion Pharmaceuticals Inc.
Phase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND Fourth FDA Division to Clear TSC IND CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Diffusion...
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
June 30, 2021 07:35 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...